S&P 500
5.214,08 +26,41 (+0,51%) Nasdaq
16.346,26 +43,46 (+0,27%) NIKKEI 225
38.318,17 +244,19 (+0,64%) Dólar/Euro
1,0778 -0,0006 (-0,05%) Petróleo Brent
84,30 +0,42 (+0,50%) Bitcoin EUR
58.399,92 +1.231,91 (+2,15%)
NLS Pharmaceutics Ltd. (NLSP)
Después del cierre:
NLS Pharmaceutics Ltd.
The Circle 6
Zurich 8058
Switzerland
41 44 512 21 50
https://nlspharma.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Alexander Zwyer M.B.A. | President, CEO & Director | 1,07M | N/A | 1969 |
| Dr. George Apostol M.D. | Chief Medical Officer and Global Head of Research & Development | 154k | N/A | 1973 |
| Dr. Eric Konofal M.D., Ph.D. | Co-Founder & Chief Scientific Officer | N/A | N/A | 1967 |
| Ms. Elena Thyen-Pighin | Chief Financial Officer | N/A | N/A | N/A |
| Dr. Christian C. Wenger Dr. iur., L.L.M., Ph.D. | General Counsel | N/A | N/A | 1964 |
Descripción
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.
Gobierno corporativo
El ISS Governance QualityScore de NLS Pharmaceutics Ltd., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
